Equities
  • Price (CHF)205.96
  • Today's Change0.00 / 0.00%
  • Shares traded40.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Feb 05 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring solutions and pharmaceutical systems. The Company's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

  • Revenue in USD (TTM)20.18bn
  • Net income in USD1.73bn
  • Incorporated1906
  • Employees73.00k
  • Location
    Becton Dickinson and CoOne Becton DriveFRANKLIN LAKES 07417-1880United StatesUSA
  • Phone+1 (201) 847-6800
  • Websitehttps://www.bd.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BDX:NYQ since
announced
Transaction
value
Edwards Lifesciences Corp-Critical Care businessDeal completed03 Jun 202403 Jun 2024Deal completed-2.93%4.20bn
Data delayed at least 15 minutes, as of Nov 21 2024 16:32 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.